Health Catalyst, Inc. (NASDAQ:HCAT) Receives $2.45 Consensus PT from Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been assigned an average rating of “Hold” from the eleven research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $2.45.

HCAT has been the topic of a number of research analyst reports. Canaccord Genuity Group restated a “hold” rating and issued a $1.80 target price (down from $3.00) on shares of Health Catalyst in a research note on Thursday, August 20th. Weiss Ratings upgraded Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Citigroup dropped their price objective on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Wells Fargo & Company reduced their price objective on Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a report on Thursday, August 13th. Finally, Stephens decreased their target price on Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th.

Institutional Trading of Health Catalyst

Several institutional investors and hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC lifted its stake in Health Catalyst by 1,214.8% in the second quarter. Squarepoint Ops LLC now owns 400,210 shares of the company’s stock worth $796,000 after acquiring an additional 369,772 shares during the period. AXQ Capital LP purchased a new position in Health Catalyst during the 2nd quarter valued at about $38,000. Headlands Technologies LLC purchased a new position in Health Catalyst during the 2nd quarter valued at about $131,000. Hsbc Holdings PLC raised its holdings in shares of Health Catalyst by 313.3% in the 2nd quarter. Hsbc Holdings PLC now owns 408,634 shares of the company’s stock valued at $809,000 after purchasing an additional 309,766 shares in the last quarter. Finally, Palogic Value Management L.P. bought a new stake in shares of Health Catalyst in the 2nd quarter valued at about $9,796,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Stock Up 0.6%

NASDAQ:HCAT opened at $1.70 on Friday. Health Catalyst has a twelve month low of $0.96 and a twelve month high of $3.62. The company has a market cap of $127.94 million, a price-to-earnings ratio of -0.46 and a beta of 1.53. The stock has a fifty day simple moving average of $1.96 and a 200-day simple moving average of $1.64. The company has a current ratio of 2.70, a quick ratio of 2.70 and a debt-to-equity ratio of 1.51.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. The firm had revenue of $70.49 million for the quarter, compared to analysts’ expectations of $69.09 million. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.83%. Analysts anticipate that Health Catalyst will post -0.18 EPS for the current year.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.